Increased resistance to infection with BruceUla abortus 2308 resulted when recombinant murine gamma interferon (rMuIFN-y) was given to mice both before and during infection but not when given only before infection. Mice given rMuIFN-y had enhanced peritoneal and splenic macrophage bactericidal activity against B. aborus. Treatment of mice with rMuIFN-y plus indomethacin did not further enhance resistance to infection or macrophage bactericidal activity compared with that after treatment of mice with rMuIFN-y alone.
with L. monocytogenes (3) and M. intracellulare (6) . Collectively, these studies suggest that L. monocytogenes, M. intracellulare, and M. avium establish persistent infections by inducing macrophage production of prostaglandin E2 or other immunosuppressive cyclooxygenase metabolites (5, 6, 15, 18, 22) .
Brucella abortus is also an important bacterial pathogen that survives within murine, human, and bovine macrophages (14) . Bovine infections with B. abortus are an economically important problem in the United States (4) and a worldwide public health concern, especially in countries where brucellosis in cattle remains a widespread zoonotic problem (13, 23) . It is unknown whether rMuIFN-y therapy can enhance resistance of mice to infection with B. abortus as has been shown to occur with infections with L. monocytogenes (11) and M. intracellulare and M. tuberculosis (6, 10) . The modulatory role of suppressive cyclooxygenasederived prostaglandins in murine immunity to Brucella infection is also unknown. In the current study, the role of IFN--y and prostaglandins in murine immunity to Brucella infection was investigated by examining the capacity of rMuIFN--y and INDO therapy to enhance resistance of mice to infection with B. abortus.
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Drug preparation and treatment of mice. The nonglycosylated rMuIFN--y (lot no. 2271-54-F2) was a gift from Genentech Inc. (South San Francisco, Calif.), had a specific activity of 8.0 x 106 U/ml, and contained less than 1 ng of endotoxin per ml. INDO (Sigma Chemical Co., St. Louis, Mo.) was solubilized in 95% ethanol at 10 mg/ml, filter sterilized, and stored in the dark at 4°C for no longer than 2 days before use. The rMuIFN--y was diluted with NaCl saline (0.15 M, pH 7.2), and INDO was diluted with phosphate-buffered saline (PBS; 0.01 M, pH 7.2) immediately before the mice were injected. Male 8-week-old BALB/c mice were obtained from Charles River Breeding Laboratories Inc. (Wilmington, Mass.) and used in the experiments when they were 10 to 12 weeks old. Mice received rMuIFN--y by an intramuscular (i.m.) injection in the femoral muscles (0.1 ml; 5,000, 50,000, or 500,000 U per mouse) and INDO by a subcutaneous injection in the dorsal lumbosacral region (0.1 ml; 2 mg/kg of body weight). Control mice were given an i.m. injection with 0.1 ml of NaCl saline and a subcutaneous injection with 0.1 ml of 0.5% ethanol in PBS.
Resistance of mice to infection with B. abortus. B. abortus 2308 was grown on potato infusion agar and prepared for infecting mice as previously described (16) . Mice received between 1 x 104 and 2 x 10 viable B. abortus CFU in 0.2 ml of NaCl saline by an intraperitoneal injection. The number of B. abortus CFU per spleen was determined at 7 days after mice were infected as previously described (16 (Table 1) .
Macrophage bactericidal activity against B. abortus. Erythrocyte-free peritoneal and spleen cell suspensions were prepared from mice as previously described (1, 12) . The cells were suspended in RPMI 1640 medium (GIBCO Laboratories, Grand Island, N.Y.) containing 5% fetal bovine serum (HyClone Laboratories, Inc., Logan, Utah). A 100-pl aliquot containing 105 peritoneal cells or 5 x 105 spleen cells was added to three separate flat-bottom wells of a 96-well microtiter plate. Plates were incubated for 2 h at 37°C in 5% CO2, and the nonadherent cells were removed by washing. Cultures of B. abortus 2308 were prepared as previously described (16) . Fifty microliters of RPMI containing 5% fetal bovine serum and 2 x 106 B. abornus CFU was added to each of the three wells containing the macrophages, which resulted in approximately 20 bacteria per macrophage. Bacteria were pelleted onto the macrophage monolayers by centrifuging plates at 1,600 x g for 5 min. The plates and the B. abortus suspension added to macrophages were incubated for 1 h at 37°C. The macrophages were then lysed by adding 50 pl of 0.2% saponin (Sigma) in PBS. The tetrazolium compound 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTI; Sigma) was added, and the number of B. abortus CFU that were killed by macrophages was quantitated by colorimetrically measuring conversion of MiT to formazan by live B. abortus as previously described (21) .
Bactericidal activity in vitro against B. abornus by peritoneal macrophages, but not splenic macrophages, was significantly (P c 0.05) increased at 24 h after mice received 50,000 or 500,000 U of rMuIFN-y (Table 2) . At 48 h after mice received 50,000 and 500,000 U of rMuIFN--y, both splenic and peritoneal macrophage bactericidal activities were significantly (P c 0.05) increased compared with those of macrophages from untreated control mice. Treatment of mice with 5,000, 50,000, or 500,000 U of rMuIFN--y resulted in a dose-dependent increase in spleen weights at 24 and 48 h after treatment (Table 2 ). Spleen weights were significantly (P < 0.05) increased at 24 h after mice received 50,000 or 500,000 U and at 48 h after animals received 500,000 U (P c 0.05). The enlarged spleens of mice given rMuIFN-y were normal when examined histologically (data not shown). Spleen weights and in vitro splenic and peritoneal macrophage bactericidal activities returned to control levels at 72 h after mice received rMuIFN-y (data not shown). Mice treated with rMuIFN-y (5,000, 50,000, or 500,000 U) plus 2 mg of INDO per kg did not have spleen weights or in vitro splenic and peritoneal macrophage bactericidal activities at 24, 48, and 72 h after treatment that were different from those of mice given rMuIFN-y alone (data not shown).
This study showed that rMuIFN--y or INDO therapy enhanced resistance of mice to B. abortus infection as assessed by measurement of decreased numbers of B. abortus CFU per spleen in infected animals. Mice given rMuIFN-,y plus INDO did not have further enhanced resistance compared with mice given rMuIFN-y or INDO alone. Effective treatment with rMuIFN-y (5,000 or 50,000 U per mouse) occurred when it was given to mice at 1 day before and again at 2 and 4 days after infection with B. abortus. Mice given low (5,000-U), moderate (50,000-U), or very high (500,000-U) concentrations of rMuIFN--y at 1 day before or both 1 and 2 days before infection with B. abortus did not have increased resistance to infection. These results suggest that rMuIFN--y is an effective therapeutic agent when given both before and during infection with B. abortus but not when given only before infection.
In initial studies, it was established that daily treatment of mice with 2 mg of INDO per kg for 2 days decreased cyclooxygenase activity in spleen cells by 80 to 90% as assessed by measuring cyclooxygenase production of prostaglandin E2 by a radioimmunoassay (unpublished data). Mice were given 2 mg of INDO per kg daily for no longer than 7 consecutive days because this is the maximum nontoxic treatment regimen that can be used in these animals (3, 9) . Daily treatment of mice for 7 consecutive days with INDO beginning 1 day before animals were infected with B. abortus decreased the number of CFU per spleen. These results suggest that inhibition of cyclooxygenase activity by INDO in B. aborus-infected mice increases clearance of bacteria from the spleen. The reduction of bacteria in the spleen that occurred with seven consecutive daily injections of mice with INDO in our study was very similar to that seen when we gave mice three injections of rMuIFN--y during the same 7-day interval. Similar results have been reported in other studies that have shown that INDO when given daily for 7 days to mice decreases M. intracellulare infection of the spleen and lung in a similar manner as did daily treatment of mice for 7 days with rMuIFN--y (6). It has also been shown that mice given INDO daily for 6 days have enhanced survival of infection with L. monocytogenes (3) . These studies indicate that INDO treatment of Listeria-and Mycobacterium-infected mice increases bacterial clearance. Our results suggest that INDO also provides a similar benefit when given to Brucella-infected mice.
INDO is a potent inhibitor of cyclooxygenase activity (7), and it is widely believed that its immunostimulatory action results from inhibiting production of prostaglandin E2 and other cyclooxygenase-derived suppressive prostaglandins (2, 8) . In the current study, INDO or rMuIFN-y therapy alone effectively enhanced resistance of mice to infection with B. aborts. However, combined therapy with INDO and rMuIFN--y was no more effective than either of these treatments used alone. A possible explanation for these results is that INDO, by presumably blocking production of cyclooxygenase-derived suppressive prostaglandins, enabled increased endogenous cytokine production to occur in B. abortus-infected mice. Thus, INDO-treated mice may have been able to produce sufficient levels of endogenous cytokines to combat the B. abortus infection effectively; therefore, the additional treatment of these animals with exogenous rMuIFN--y was unable to produce any further therapeutic effect. Others have proposed that INDO enhances resistance of mice to Mycobactenium infection by blocking cyclooxygenase production of prostaglandin E2, which subsequently enhances endogenous production of IFN--y and other cytokines that stimulate macrophage bactericidal activity against Mycobacterium infection (6) .
We showed that a single injection of 50,000 or 500,000 U of rMuIFN--y per mouse stimulated the immune system, as evident by splenomegaly and increased splenic and peritoneal macrophage bactericidal activity against B. abotus. However, these effects were transient in that they persisted for no longer than 48 h. This transiently enhanced macrophage bactericidal activity induced by rMuIFN-y may explain why rMuIFN--y enhanced resistance when given to mice both before and during the B. abotus infection but not when given only before infection. Perhaps continued periodic treatment of B. abotus-infected mice with rMuIFN--y during the infection is required to sustain enhanced macrophage bactericidal activity that aids in eliminating the bacteria.
